Lanreotide in metastatic enteropancreatic neuroendocrine tumors. [electronic resource]
Producer: 20140723Description: 224-33 p. digitalISSN:- 1533-4406
- Aged
- Antineoplastic Agents -- adverse effects
- Delayed-Action Preparations
- Diarrhea -- etiology
- Disease-Free Survival
- Double-Blind Method
- Female
- Gastrointestinal Neoplasms -- drug therapy
- Humans
- Male
- Middle Aged
- Neuroendocrine Tumors -- drug therapy
- Pancreatic Neoplasms -- drug therapy
- Peptides, Cyclic -- adverse effects
- Somatostatin -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.